Notably, the clinical trials MAGMA and JCOG1703 further demonstrated that some treatment regimens for newly diagnosed GBMs ...
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, ...
The increasing global burden of chronic diseases, coupled with the need for sustainable and health-promoting dietary strategies, has positioned functional ...
aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C ...
A B.tech graduate in Mechanical Engineering and an avid automobile enthusiast, Arun has been passionate about cars and bikes since his formative years. The affection led him to pursue Automotive ...
KEDRAB/KAMRAB: Kamada's proprietary anti-rabies immunoglobulin distributed in the U.S. and international markets. CYTOGAM: A plasma-derived immunoglobulin targeting cytomegalovirus (CMV), primarily ...
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...
Detailed price information for Galmed Pharmaceutica (GLMD-Q) from The Globe and Mail including charting and trades.
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans ...
Morning Overview on MSN
Scientists discover vitamin B2 secretly shields cancer cells from death — and blocking it made tumors vulnerable to a single compound
Cancer cells have a survival trick that nobody expected: they co-opt vitamin B2, one of the most ordinary nutrients in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results